Collection, manipulation and freezing of haemopoietic stem cells

Gorin, NC

doi:10.1016/s0308-2261(86)80004-2

Cited by 107 publications

(44 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If necessary, a second leukapheresis was performed the following day. 13,14 In order to prevent clotting, ACD was used at a ratio of 1:12 for children weighing 25 kg or more; for children under 25 kg, 1:16 ACD was combined with heparin 50 U/kg, and the separator was initialized with a compatible filtered and irradiated red blood cell unit, suspended in 4% albumin, up to the patient's hematocrit, to avoid transient hypovolemia, due to the volume sequestered in the separator. 15 It was common practice to collect large CD34 + cell amounts in order to allow purification and storage of an unmanipulated fraction of the CD34 + cells collected, to be used for rescue in the event of purification procedure failure or of non-engrafment.…”

Section: Methodsmentioning

confidence: 99%

Peripheral blood stem cell collection in children with acute leukemia: effectiveness of the ‘DIAVE’ mobilizing regimen

Balduzzi

Perseghin

Dassi

et al. 2002

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Few experiences of peripheral blood (PB) hematopoietic stem cell mobilization for autologous transplantation have been reported to date in children with acute leukemia (AL). The five-drug-chemotherapy 'DIAVE' (dexamethazone, idarubicine, cytosine-arabinoside, vincristine, etoposide), followed by G-CSF, previously reported as consolidation, was adopted as a mobilization regimen in 29 children (median age: 8 years, range: 3-21; median weight: 34 kg, range: 15-73) with ALL in second remission (CR2: 21), in CR3 (2) or ANLL in CR1 (6). A median peak of 94 ؋ 10 6 CD34 + cells/l (range: 10-604) was reached at a median time of 12 days (range: 10-18) after the beginning of the mobilizing regimen, which was well tolerated. A median of 10.9 ؋ 10 6 CD34 + cells/kg (range: 2.4-56.6) were collected in 25 patients (86%), approaching 40 ؋ 10 6 /l CD34 + cells in the PB (ALL in CR2: 20/21, in CR3: 0/2; ANLL: 5/6) by means of one (20) or two (5) leukaphereses; a median of 2.5 blood volumes was processed. Patients with ANLL mobilized more cells than patients with ALL; moreover, the shorter the interval between remission and mobilizing therapy, the higher was the yield. The products collected underwent purification, aiming at achieving complete removal of possibly contaminating leukemic cells, in 21 cases; also, unmanipulated aliquots were stored as rescues for all but one patient. All the 23 patients undergoing transplantation engrafted (ANC Ͼ0.5 ؋ 10 9 /l) at a median of 12 days. In conclusion, the DIAVE regimen compares favorably with conventional mobilizing regimens, usually containing cyclophosphamide, in terms of low toxicity, collection time predictability, and efficacy, as shown by the high proportion of patients mobilizing, the large amounts of stem cell collected by means of one or two leukaphereses only, and the prompt engraftment after infusion.

show abstract

Section: Methodsmentioning

confidence: 99%

Peripheral blood stem cell collection in children with acute leukemia: effectiveness of the ‘DIAVE’ mobilizing regimen

Balduzzi

Perseghin

Dassi

et al. 2002

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…3 Briefly, buffy coat cells were obtained by centrifugation of the graft with the Cobe cell washer (Cobe, Lakewood, CO, USA). The graft was then cooled to 4°C and resuspended with 10% DMSO for cryopreservation.…”

Section: Hemopoietic Stem Cell Processing and Infusionmentioning

confidence: 99%

“…[1][2][3][4][5] The incidence of lethal complications related to autologous transplant resulting from the intensive cytotoxic preparative regimen and bone marrow aplasia is usually low; some authors, however, report that cryopreserved marrow infusion may induce complications ranging from nausea, vomiting, abdominal pain, hypotension to life-threatening renal failure or cardiac arrhythmias. [6][7][8][9][10][11][12] The use of DMSO has been implicated in the pathogenesis of cardiovascular and other changes observed during infusion; other authors suggest that damaged cells and lysis products may play a role.…”

mentioning

confidence: 99%

Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases

Alessandrino

Bernasconi

Caldera

et al. 1999

Bone Marrow Transplant

134

121

View full text Add to dashboard Cite

Summary:Bone marrow (BM) and/or peripheral blood progenitor cells (PBPC) given after high-dose chemo-radiotherapy are commonly cryopreserved. Re-infusion of the thawed product can cause cardiovascular and other complications. We compared two groups of adult patients receiving autologous BM or PBPC transplant to assess the incidence of adverse events occurring during infusion. Fifty-one patients received BM, and 75 PBPC. The two groups were comparable in respect of age, total volume infused, quantity of dimethylsulfoxide (DMSO) and number of polymorphonuclear neutrophils. Patients receiving PBPC had a higher number of nucleated cells per kg of body weight; those in the BM group received a significantly greater quantity of red cells. Non-cardiovascular complications occurred in 19% and 8% of patients rescued by BM and PBPC respectively. The incidence of hypertension was 21% in the BM and 36% in the PBPC group. Asymptomatic hypotension was more frequent in PBPC patients (P Ͻ 0.001). Bradyarrhythmia was noticed in two of 75 PBPC patients and in 14 of 51 BM patients (P Ͻ 0.001). In the former group one patient had heart block; he died of renal failure 10 days later. Bradycardia and hemoglobinuria were more common in patients receiving BM where a higher concentration of red cells was present (P Ͻ 0.001). Since bradyarrhythmias may be a life-threatening complication we advise continuous careful monitoring during infusion of thawed BM. The strong correlation between bradycardia and red blood cell contamination suggests the use of purified products with a very low red cell content.

show abstract

“…The BM was collected as per standard procedure. 7 PBSCs were mobilized after high-dose chemotherapy followed by G-CSF 10 g/kg/day s.c. and collected by means of a continuous flow cell separator (Cobe Spectra; Cobe, Lakewood, CO, USA). Seven aphereses were not manipulated; in 17 cases PB manipulations consisted of negative selection for ALL (n ϭ 12) and positive selection for ANLL (n ϭ 5), performed by a SuperMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany) as described by Rambaldi et al 8 SCs were frozen regardless of their nucleated cell concentration, without further centrifugation or dilution steps, 9 by slowly adding ACD-A (Baxter, Deerfield, IL, USA) and DMSO (Merck, Sharp & Dome, Darmstadt, Germany) in melting ice, up to a final concentration of 10% for both additives and then transferred into a freezing bag (NPBI, Emmer, The Netherlands).…”

Section: Infusion-related Side-effects In Children Undergoing Autologmentioning

confidence: 99%

“…Viability was assessed by the 0.4% Trypan Blue dye exclusion method. 7 Blood chemistries were determined before and the day after infusion; urinalysis was performed twice daily. Myeloid engraftment was defined as the first of 3 consecutive days with an ANC Ͼ1 ϫ 10 3 /l and platelet engraftment as the first of 5 consecutive days with a platelet count Ͼ20 ϫ 10 3 /l without transfusion support.…”

Section: Infusion-related Side-effects In Children Undergoing Autologmentioning

confidence: 99%

Infusion-related side-effects in children undergoing autologous hematopoietic stem cell transplantation for acute leukemia

Perseghin¹,

Balduzzi

Bonanomi

et al. 2000

Bone Marrow Transplant

View full text Add to dashboard Cite

Collection, manipulation and freezing of haemopoietic stem cells

Cited by 107 publications

References 112 publications

Peripheral blood stem cell collection in children with acute leukemia: effectiveness of the ‘DIAVE’ mobilizing regimen

Peripheral blood stem cell collection in children with acute leukemia: effectiveness of the ‘DIAVE’ mobilizing regimen

Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases

Infusion-related side-effects in children undergoing autologous hematopoietic stem cell transplantation for acute leukemia

Contact Info

Product

Resources

About